India Globalization Capital, Inc.: management transactions · United States · SEC (Form 4)

About India Globalization Capital, Inc.

India Globalization Capital, Inc., now operating as IGC Pharma, Inc., is a U.S.-listed company traded on the NYSE/NASDAQ framework and headquartered in Potomac, Maryland, United States. The company was incorporated in Maryland in April 2005 and initially launched as a blank-check acquisition vehicle before transitioning into an operating business. For investors, the essential point is that the company has evolved into a health-care and life-sciences story, while still retaining a legacy infrastructure business that remains part of its historical operating base. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1326205/000118518526000941/igc10kt123125.htm?utm_source=openai)) IGC Pharma’s current strategic identity is that of a clinical-stage biotechnology company focused on neuropsychiatric and neurodegenerative disorders, with Alzheimer’s disease at the center of its pipeline. Recent company disclosures and investor communications highlight a lead program, IGC-AD1, and the CALMA Phase 2 trial targeting agitation in Alzheimer’s dementia. Management also emphasizes the use of artificial intelligence to support drug discovery, patient targeting, and trial optimization, which suggests an effort to differentiate the platform beyond a single asset. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1326205/000118518526000941/igc10kt123125.htm?utm_source=openai)) The company’s business model is still mixed. In its SEC filings, IGC describes a legacy infrastructure segment that includes heavy equipment rental, trading in infrastructure-related commodities, and real estate management. At the same time, the company’s life-sciences activities are increasingly the main market narrative, with research and development, product formulation, and clinical development taking center stage. IGC also notes operating presence beyond headquarters, including facilities in Vancouver, Washington, used for manufacturing, sales, and distribution tied to its life-sciences segment. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1326205/000118518524000650/igcpharma20240331_10k.htm?utm_source=openai)) From a competitive standpoint, IGC should be viewed as a small-cap, high-risk development-stage biotech rather than a mature pharmaceutical company. Its competitive strengths lie in a focused pipeline, a patent-oriented approach, and the potential optionality of cannabinoid-based therapies and related research programs. The company’s filings indicate a structure supported by subsidiaries and continued capital markets access, which is common for clinical-stage biotechs that are still funding development rather than generating meaningful commercial revenue. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1326205/000118518526000941/igc10kt123125.htm?utm_source=openai)) Recent corporate events are important for investors tracking Form 4 insider activity. The company changed its name to IGC Pharma, Inc., reinforcing its pivot toward pharmaceuticals and life sciences. In December 2025, it also increased authorized common shares from 150 million to 600 million, a material governance and dilution consideration for equity holders. Recent SEC filings, including Form 4 and related ownership disclosures, show ongoing insider reporting and active capital-structure management, underscoring that the stock remains a closely watched U.S. listed name in the biotechnology space. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1326205/000118518526000030/igc424b5010526.htm?utm_source=openai))